Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/AGIO/Catalyst
Phase 1bData readout

AG-181

Phenylketonuria

AGIOAgios Pharmaceuticals Inc.
Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset
AG-181
Development stage
Phase 1b
Event type
Data readout
Indication
Phenylketonuria

Research summary

What is being tracked?

This catalyst tracks a Phase 1b data readout for AG-181 in Phenylketonuria. The expected timing is based on the latest available company guidance and may change.

Development notes

07/30/26:- AG-181 Ph1b dosed first PKU patient; data expected H2 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from AGIO

Related pipeline programs

Approved

PYRUKYND (Mitapivat)

Beta thalessemia

View company pipeline
PDUFA

PYRUKYND (Mitapivat)

Sickle cell disease, Anemia

View company pipeline
Failed

Tebapivat

Sickle cell disease, Blood disorder

View company pipeline
Failed

Tebapivat (AG-946)

Myelodysplastic syndrome

View company pipeline

Company

Agios Pharmaceuticals Inc.

AGIO · NasdaqGS
Industry
Biotechnology
Pipeline assets
12
View AGIO research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy